The Deubiquitinating Enzyme Inhibitor PR-619 is a Potent DNA Topoisomerase II Poison

被引:7
作者
Cowell, Ian G. [1 ]
Ling, Elise M. [1 ]
Swan, Rebecca L. [1 ]
Brooks, Matilda L. W. [1 ]
Austin, Caroline A. [1 ]
机构
[1] Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
基金
英国生物技术与生命科学研究理事会;
关键词
SMALL-MOLECULE INHIBITOR; CLEAVABLE COMPLEXES; IN-VIVO; BETA; ALPHA; BINDING; CONJUGATION; ACTIVATION; LONGEVITY; LEUKEMIA;
D O I
10.1124/mol.119.117390
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
2,6-Diaminopyridine-3,5-bis(thiocyanate) (PR-619) is a broad-spectrum deubiquitinating enzyme (DUB) inhibitor that has been employed in cell-based studies as a tool to investigate the role of ubiquitination in various cellular processes. Here, we demonstrate that in addition to its action as a DUB inhibitor, PR-619 is a potent DNA topoisomerase II (TOP2) poison, inducing both DNA topoisomerase IIa (TOP2A) and DNA topoisomerase IIb (TOP2B) covalent DNA complexes with similar efficiency to the archetypal TOP2 poison etoposide. However, in contrast to etoposide, which induces TOP2-DNA complexes with a pan-nuclear distribution, PR-619 treatment results in nucleolar concentration of TOP2A and TOP2B. Notably, neither the induction of TOP2-DNA covalent complexes nor their nucleolar concentration are due to TOP2 hyperubiquitination since both occur even under conditions of depleted ubiquitin. Like etoposide, since PR-619 affected TOP2 enzyme activity in in vitro enzyme assays as well as in live cells, we conclude that PR-619 interacts directly with TOP2A and TOP2B. The concentration at which PR-619 exhibits robust cellular DUB inhibitor activity (5-20 mM) is similar to the lowest concentration at which TOP2 poison activity was detected (above 20 mM), which suggests that caution should be exercised when employing this DUB inhibitor in cell-based studies.
引用
收藏
页码:562 / 572
页数:11
相关论文
共 24 条
  • [11] Quantification of single-strand DNA lesions caused by the topoisomerase II poison etoposide using single DNA molecule imaging
    Singh, Vandana
    Johansson, Pegah
    Ekedahl, Elina
    Lin, Yii-Lih
    Hammarsten, Ola
    Westerlund, Fredrik
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022, 594 : 57 - 62
  • [12] Selection of DNA Cleavage Sites by Topoisomerase II Results from Enzyme-Induced Flexibility of DNA
    Jang, Yunsu
    Son, Heyjin
    Lee, Sang-Wook
    Hwang, Wonseok
    Jung, Seung-Ryoung
    Byl, Jo Ann W.
    Osheroff, Neil
    Lee, Sanghwa
    CELL CHEMICAL BIOLOGY, 2019, 26 (04): : 502 - +
  • [13] Synthesis, crystal structure, DNA interaction and in vitro anticancer activity of a Cu(II) complex of purpurin: dual poison for human DNA topoisomerase I and II
    Das, Piyal
    Jain, Chetan Kumar
    Dey, Sanjoy K.
    Saha, Rajat
    Chowdhury, Abhishek Dutta
    Roychoudhury, Susanta
    Kumar, Sanjay
    Majumder, Hemanta Kumar
    Das, Saurabh
    RSC ADVANCES, 2014, 4 (103) : 59344 - 59357
  • [14] Synthesis and biological activity of 2,4-di-p-phenolyl-6-2-furanyl-pyridine as a potent topoisomerase II poison
    Karki, Radha
    Park, Chanmi
    Jun, Kyu-Yeon
    Kadayat, Tara Man
    Lee, Eung-Seok
    Kwon, Youngjoo
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 90 : 360 - 378
  • [15] Casein kinase II-dependent phosphorylation of DNA topoisomerase II suppresses the effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast
    Nakazawa, Norihiko
    Arakawa, Orie
    Ebe, Masahiro
    Yanagida, Mitsuhiro
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (10) : 3772 - 3782
  • [16] Identification of potent catalytic inhibitors of human DNA topoisomerase II by structure-based virtual screening
    Dong, Guoqiang
    Wu, Ying
    Sun, Ying
    Liu, Na
    Wu, Shanchao
    Zhang, Wannian
    Sheng, Chunquan
    MEDCHEMCOMM, 2018, 9 (07) : 1142 - 1146
  • [17] The Polyphenolic Ellagitannin Vescalagin Acts As a Preferential Catalytic Inhibitor of the α Isoform of Human DNA Topoisomerase II
    Auzanneau, Celine
    Montaudon, Daniele
    Jacquet, Remi
    Puyo, Stephane
    Pouysegu, Laurent
    Deffieux, Denis
    Elkaoukabi-Chaibi, Assia
    De Giorgi, Francesca
    Ichas, Francois
    Quideau, Stephane
    Pourquier, Philippe
    MOLECULAR PHARMACOLOGY, 2012, 82 (01) : 134 - 141
  • [18] Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage
    Kerestes, Veronika
    Kubes, Jan
    Applova, Lenka
    Kollarova, Petra
    Lencova-Popelova, Olga
    Melnikova, Iuliia
    Karabanovich, Galina
    Khazeem, Mushtaq M.
    Bavlovic-Piskackova, Hana
    Sterbova-Kovarikova, Petra
    Austin, Caroline A.
    Roh, Jaroslav
    Sterba, Martin
    Simunek, Tomas
    Jirkovska, Anna
    TOXICOLOGICAL SCIENCES, 2024, 198 (02) : 288 - 302
  • [19] The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
    Yamamoto, Kotaro
    Kokubun, Taiki
    Sato, Kota
    Akaishi, Takahiro
    Shimazaki, Atsushi
    Nakamura, Masatsugu
    Shiga, Yukihiro
    Tsuda, Satoru
    Omodaka, Kazuko
    Saya, Hideyuki
    Nakazawa, Toru
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [20] Design, Synthesis and in vitro Anticancer Activity of a Cu(II) Complex of Carminic Acid: A Novel Small Molecule Inhibitor of Human DNA Topoisomerase I and Topoisomerase II
    Das, Piyal
    Jain, Chetan Kumar
    Roychoudhury, Susanta
    Majumder, Hemanta Kumar
    Das, Saurabh
    CHEMISTRYSELECT, 2016, 1 (21): : 6623 - 6631